Trade Takeda Pharmaceutical Company Limited - 4502 CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 31.34 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.010938% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.011284% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 4277.82 |
| Open* | 4311.94 |
| 1-Year Change* | 19.79% |
| Day's Range* | 4267.46 - 4319.72 |
| 52 wk Range | 3,455.00-4,478.00 |
| Average Volume (10 days) | 5.57M |
| Average Volume (3 months) | 88.58M |
| Market Cap | 6,795.96B |
| P/E Ratio | 24.41 |
| Shares Outstanding | 1.55B |
| Revenue | 3,944.61B |
| EPS | 175.97 |
| Dividend (Yield %) | 4.19092 |
| Beta | 0.99 |
| Next Earnings Date | May 11, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2023 | 4275.94 | -37.89 | -0.88% | 4313.83 | 4320.92 | 4271.94 |
| Mar 27, 2023 | 4277.82 | 6.38 | 0.15% | 4271.44 | 4289.80 | 4258.08 |
| Mar 24, 2023 | 4254.99 | 11.77 | 0.28% | 4243.22 | 4267.86 | 4224.16 |
| Mar 23, 2023 | 4252.60 | -32.31 | -0.75% | 4284.91 | 4286.90 | 4240.03 |
| Mar 22, 2023 | 4358.72 | -55.75 | -1.26% | 4414.47 | 4414.47 | 4352.73 |
| Mar 20, 2023 | 4283.82 | -61.23 | -1.41% | 4345.05 | 4347.74 | 4282.72 |
| Mar 17, 2023 | 4369.09 | 34.51 | 0.80% | 4334.58 | 4382.66 | 4320.91 |
| Mar 16, 2023 | 4273.94 | 6.88 | 0.16% | 4267.06 | 4292.79 | 4244.02 |
| Mar 15, 2023 | 4332.19 | 30.12 | 0.70% | 4302.07 | 4332.19 | 4286.81 |
| Mar 14, 2023 | 4265.46 | 32.02 | 0.76% | 4233.44 | 4293.29 | 4206.11 |
| Mar 13, 2023 | 4279.92 | 5.49 | 0.13% | 4274.43 | 4290.30 | 4240.93 |
| Mar 10, 2023 | 4335.78 | -9.97 | -0.23% | 4345.75 | 4354.23 | 4323.71 |
| Mar 9, 2023 | 4388.64 | 54.76 | 1.26% | 4333.88 | 4390.64 | 4317.82 |
| Mar 8, 2023 | 4323.81 | 31.92 | 0.74% | 4291.89 | 4329.90 | 4289.00 |
| Mar 7, 2023 | 4289.10 | 19.16 | 0.45% | 4269.94 | 4292.89 | 4264.86 |
| Mar 6, 2023 | 4260.97 | 21.94 | 0.52% | 4239.03 | 4269.45 | 4233.94 |
| Mar 3, 2023 | 4237.04 | 46.28 | 1.10% | 4190.76 | 4252.40 | 4190.16 |
| Mar 2, 2023 | 4172.11 | 5.49 | 0.13% | 4166.62 | 4188.56 | 4155.23 |
| Mar 1, 2023 | 4165.22 | -5.09 | -0.12% | 4170.31 | 4191.16 | 4164.13 |
| Feb 28, 2023 | 4195.54 | 28.22 | 0.68% | 4167.32 | 4201.53 | 4166.22 |
Takeda Pharmaceutical Company Limited Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 3569010 | 3197810 | 3291190 | 2097220 | 1770530 |
| Revenue | 3569010 | 3197810 | 3291190 | 2097220 | 1770530 |
| Cost of Revenue, Total | 1106850 | 994308 | 1089760 | 651729 | 495921 |
| Gross Profit | 2462160 | 2203500 | 2201420 | 1445500 | 1274610 |
| Total Operating Expense | 3123810 | 2596860 | 3193730 | 1874650 | 1531000 |
| Selling/General/Admin. Expenses, Total | 886361 | 875663 | 964737 | 717599 | 628106 |
| Research & Development | 526087 | 455833 | 492381 | 368298 | 325441 |
| Depreciation / Amortization | 472915 | 421864 | 455420 | 178617 | 122131 |
| Unusual Expense (Income) | 100290 | -265230 | 189043 | -41201 | 28183 |
| Other Operating Expenses, Total | 31309 | 114422 | 2384 | -2507 | -3907 |
| Operating Income | 445198 | 600952 | 97459 | 222577 | 239528 |
| Interest Income (Expense), Net Non-Operating | -142628 | -234717 | -158213 | -94965 | -22323 |
| Other, Net | 1 | ||||
| Net Income Before Taxes | 302571 | 366235 | -60754 | 127612 | 217205 |
| Net Income After Taxes | 230166 | 376171 | 44290 | 135080 | 186708 |
| Minority Interest | -107 | -166 | -49 | 112 | 178 |
| Net Income Before Extra. Items | 230059 | 376005 | 44241 | 135192 | 186886 |
| Net Income | 230059 | 376005 | 44241 | 135192 | 186886 |
| Income Available to Common Excl. Extra. Items | 230059 | 376005 | 44241 | 135192 | 186886 |
| Income Available to Common Incl. Extra. Items | 230059 | 376005 | 44241 | 135192 | 186886 |
| Diluted Net Income | 230059 | 376005 | 44241 | 135192 | 186886 |
| Diluted Weighted Average Shares | 1577.17 | 1573.54 | 1566.2 | 966.897 | 786.69 |
| Diluted EPS Excluding Extraordinary Items | 145.868 | 238.955 | 28.2473 | 139.82 | 237.56 |
| Dividends per Share - Common Stock Primary Issue | 180 | 180 | 180 | 180 | 180 |
| Diluted Normalized EPS | 194.24 | 129.394 | 106.703 | 112.123 | 268.355 |
| Interest Expense (Income) - Net Operating | 2112 | -64872 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 873289 | 901294 | 844819 | 949603 | 770274 |
| Revenue | 873289 | 901294 | 844819 | 949603 | 770274 |
| Cost of Revenue, Total | 308380 | 281404 | 275797 | 241264 | 253446 |
| Gross Profit | 564909 | 619890 | 569022 | 708339 | 516828 |
| Total Operating Expense | 874908 | 784810 | 747392 | 701051 | 619734 |
| Selling/General/Admin. Expenses, Total | 223429 | 231078 | 212011 | 219843 | 234388 |
| Research & Development | 143628 | 128378 | 131600 | 122480 | 113289 |
| Depreciation / Amortization | 149283 | 118087 | 102721 | 102824 | 114294 |
| Unusual Expense (Income) | 33062 | 26767 | 27979 | 16751 | 29440 |
| Other Operating Expenses, Total | 17126 | -904 | -2716 | -2111 | -125123 |
| Operating Income | -1619 | 116484 | 97427 | 248552 | 150540 |
| Interest Income (Expense), Net Non-Operating | -52429 | -44291 | -35980 | -25574 | -19662 |
| Net Income Before Taxes | -54047 | 72193 | 61447 | 222978 | 130878 |
| Net Income After Taxes | -11375 | 57820 | 45995 | 137726 | 197144 |
| Minority Interest | 17 | -51 | -31 | -43 | -46 |
| Net Income Before Extra. Items | -11358 | 57769 | 45964 | 137683 | 197098 |
| Net Income | -11358 | 57769 | 45964 | 137683 | 197098 |
| Income Available to Common Excl. Extra. Items | -11358 | 57770 | 45964 | 137684 | 197098 |
| Income Available to Common Incl. Extra. Items | -11358 | 57770 | 45964 | 137684 | 197098 |
| Diluted Net Income | -11358 | 57770 | 45964 | 137684 | 197098 |
| Diluted Weighted Average Shares | 1553.81 | 1574.97 | 1580.42 | 1574.43 | 1574.48 |
| Diluted EPS Excluding Extraordinary Items | -7.30976 | 36.68 | 29.0834 | 87.4503 | 125.183 |
| Dividends per Share - Common Stock Primary Issue | 90 | 0 | 90 | 0 | 90 |
| Diluted Normalized EPS | 6.52092 | 50.2916 | 42.335 | 94.0219 | 137.337 |
| Total Adjustments to Net Income | 1 | 0 | 1 | ||
| Other, Net | 1 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 2593640 | 2712890 | 2469430 | 2993040 | 1078810 |
| Cash and Short Term Investments | 875000 | 1002820 | 653436 | 725819 | 375186 |
| Cash & Equivalents | 389058 | 335027 | 188640 | 462890 | 243324 |
| Short Term Investments | 485942 | 667793 | 464796 | 262929 | 131862 |
| Total Receivables, Net | 724377 | 812714 | 784921 | 749119 | 428792 |
| Accounts Receivable - Trade, Net | 617518 | 707487 | 670708 | 657681 | 360833 |
| Total Inventory | 853167 | 753881 | 759599 | 919670 | 212944 |
| Other Current Assets, Total | 141098 | 143478 | 271476 | 598429 | 61886 |
| Total Assets | 13178000 | 12912300 | 12821100 | 13792800 | 4106460 |
| Property/Plant/Equipment, Total - Net | 1582800 | 1453920 | 1386370 | 1331930 | 536801 |
| Property/Plant/Equipment, Total - Gross | 2453010 | 2191740 | 2084120 | 1971520 | 1191400 |
| Accumulated Depreciation, Total | -870208 | -737818 | -697754 | -639591 | -654597 |
| Goodwill, Net | 4407750 | 4033920 | 4012530 | 4240250 | 1029250 |
| Intangibles, Net | 3818540 | 3909110 | 4171360 | 4751170 | 1014260 |
| Long Term Investments | 330133 | 348350 | 369455 | 299922 | 304385 |
| Other Long Term Assets, Total | 445150 | 454110 | 411948 | 176463 | 142957 |
| Total Current Liabilities | 2145730 | 1773180 | 2175900 | 2553050 | 737509 |
| Accounts Payable | 295933 | 232105 | 211627 | 212348 | 133705 |
| Notes Payable/Short Term Debt | 285 | 69 | 5014 | 500002 | 18 |
| Current Port. of LT Debt/Capital Leases | 203708 | 22084 | 581803 | 484944 | |
| Other Current Liabilities, Total | 1645800 | 1518920 | 1377450 | 1355760 | 603786 |
| Total Liabilities | 7495000 | 7739260 | 8097610 | 8610790 | 2109040 |
| Total Long Term Debt | 4141420 | 4613220 | 4506490 | 4766000 | 985644 |
| Long Term Debt | 4141420 | 4613220 | 4506490 | 4766000 | 985644 |
| Deferred Income Tax | 473145 | 576542 | 765079 | 783356 | 90725 |
| Minority Interest | 504 | 4140 | 4003 | 4006 | 19985 |
| Other Liabilities, Total | 734202 | 772180 | 646144 | 504372 | 275176 |
| Total Equity | 5683020 | 5173040 | 4723480 | 5181980 | 1997420 |
| Common Stock | 1676260 | 1668140 | 1668120 | 1643580 | 77914 |
| Additional Paid-In Capital | 1708870 | 1688420 | 1680290 | 1650230 | 90740 |
| Retained Earnings (Accumulated Deficit) | 1479720 | 1509910 | 1369970 | 1595430 | 1557310 |
| Treasury Stock - Common | -116007 | -59552 | -87463 | -57142 | -74373 |
| Unrealized Gain (Loss) | 22068 | 41983 | 22891 | 46380 | 73037 |
| Other Equity, Total | 912106 | 324131 | 69673 | 303499 | 272799 |
| Total Liabilities & Shareholders’ Equity | 13178000 | 12912300 | 12821100 | 13792800 | 4106460 |
| Total Common Shares Outstanding | 1550.36 | 1563.36 | 1557.77 | 1554.78 | 781.309 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 2593640 | 2477890 | 2456350 | 2476460 | 2712890 |
| Cash and Short Term Investments | 875000 | 751896 | 633623 | 684850 | 1002820 |
| Cash & Equivalents | 849695 | 724341 | 607881 | 654920 | 966222 |
| Short Term Investments | 25305 | 27555 | 25742 | 29930 | 36598 |
| Total Receivables, Net | 724377 | 756117 | 887295 | 858957 | 812714 |
| Accounts Receivable - Trade, Net | 696644 | 715515 | 843625 | 827253 | 783091 |
| Total Inventory | 853167 | 811324 | 783476 | 779148 | 753881 |
| Other Current Assets, Total | 141098 | 158556 | 151959 | 153503 | 143478 |
| Total Assets | 13178000 | 12698500 | 12560300 | 12657200 | 12912300 |
| Property/Plant/Equipment, Total - Net | 1582800 | 1493590 | 1459920 | 1452170 | 1453920 |
| Goodwill, Net | 4407750 | 4167990 | 4078370 | 4058940 | 4033920 |
| Intangibles, Net | 3818540 | 3791880 | 3783680 | 3856430 | 3909110 |
| Long Term Investments | 330133 | 334812 | 352091 | 374659 | 348350 |
| Other Long Term Assets, Total | 445150 | 432359 | 429864 | 438578 | 454110 |
| Total Current Liabilities | 2145730 | 1809250 | 1918750 | 1706780 | 1773180 |
| Accounts Payable | 516297 | 351185 | 336600 | 320645 | 343838 |
| Notes Payable/Short Term Debt | 285 | 0 | 0 | 0 | 69 |
| Current Port. of LT Debt/Capital Leases | 203708 | 122936 | 214886 | 24272 | 22084 |
| Other Current Liabilities, Total | 1425440 | 1335130 | 1367260 | 1361860 | 1407180 |
| Total Liabilities | 7495000 | 7367190 | 7236340 | 7418980 | 7739260 |
| Total Long Term Debt | 4141420 | 4231940 | 4016470 | 4381590 | 4613220 |
| Long Term Debt | 4141420 | 4231940 | 4016470 | 4381590 | 4613220 |
| Deferred Income Tax | 473145 | 589481 | 576738 | 578065 | 576542 |
| Minority Interest | 504 | 493 | 426 | 385 | 4140 |
| Other Liabilities, Total | 734202 | 736023 | 723951 | 752155 | 772180 |
| Total Equity | 5683020 | 5331330 | 5323940 | 5238260 | 5173040 |
| Common Stock | 1676260 | 1676260 | 1676260 | 1669120 | 1668140 |
| Additional Paid-In Capital | 1708870 | 1697560 | 1686490 | 1682500 | 1688420 |
| Retained Earnings (Accumulated Deficit) | 1479720 | 1466930 | 1551150 | 1503810 | 1509910 |
| Treasury Stock - Common | -116007 | -91013 | -41037 | -42344 | -59552 |
| Unrealized Gain (Loss) | 22068 | 31196 | 57646 | 41983 | |
| Other Equity, Total | 912106 | 550395 | 451066 | 367516 | 324131 |
| Total Liabilities & Shareholders’ Equity | 13178000 | 12698500 | 12560300 | 12657200 | 12912300 |
| Total Common Shares Outstanding | 1550.36 | 1557.49 | 1572.83 | 1568.66 | 1563.36 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 230166 | 376171 | 44290 | 109014 | 186708 |
| Cash From Operating Activities | 1123100 | 1010930 | 670381 | 328301 | 399200 |
| Cash From Operating Activities | 583151 | 559671 | 583649 | 272446 | 182127 |
| Non-Cash Items | 252109 | 12308 | 172928 | 39061 | -43306 |
| Cash Taxes Paid | 140423 | 201687 | 226768 | 44909 | 29883 |
| Cash Interest Paid | 108207 | 107350 | 127211 | 34914 | 8365 |
| Changes in Working Capital | 57679 | 62781 | -130486 | -92220 | 73671 |
| Cash From Investing Activities | -198125 | 393530 | 292119 | -2835700 | -93342 |
| Capital Expenditures | -186037 | -236468 | -217710 | -134114 | -128262 |
| Other Investing Cash Flow Items, Total | -12088 | 629998 | 509829 | -2701580 | 34920 |
| Cash From Financing Activities | -1070260 | -1088350 | -1005210 | 2946240 | -326226 |
| Financing Cash Flow Items | -108592 | -142352 | -132804 | -71143 | -15099 |
| Total Cash Dividends Paid | -283665 | -283357 | -282582 | -142952 | -141893 |
| Issuance (Retirement) of Stock, Net | -77531 | -2141 | -3737 | -1172 | -18756 |
| Issuance (Retirement) of Debt, Net | -600477 | -660504 | -586090 | 3161500 | -150478 |
| Foreign Exchange Effects | 28758 | 12501 | -21766 | -31269 | -4565 |
| Net Change in Cash | -116527 | 328608 | -64479 | 407571 | -24933 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 230166 | 241541 | 183721 | 137726 | 376171 |
| Cash From Operating Activities | 1123100 | 747521 | 400011 | 166858 | 1010930 |
| Cash From Operating Activities | 583151 | 430877 | 283595 | 142948 | 559671 |
| Non-Cash Items | 252109 | 187026 | 112596 | 53003 | 12308 |
| Cash Taxes Paid | 140423 | 101086 | 73872 | 35902 | 201687 |
| Cash Interest Paid | 108207 | 84917 | 52668 | 23218 | 107350 |
| Changes in Working Capital | 57679 | -111923 | -179901 | -166819 | 62781 |
| Cash From Investing Activities | -198125 | -172487 | -103349 | -70445 | 393530 |
| Capital Expenditures | -186037 | -134214 | -85783 | -42292 | -236468 |
| Other Investing Cash Flow Items, Total | -12088 | -38273 | -17566 | -28153 | 629998 |
| Cash From Financing Activities | -1070260 | -826465 | -658405 | -411038 | -1088350 |
| Financing Cash Flow Items | -108592 | -85284 | -52681 | -23218 | -142352 |
| Total Cash Dividends Paid | -283665 | -273024 | -141573 | -132032 | -283357 |
| Issuance (Retirement) of Stock, Net | -77531 | -52538 | -2542 | -2542 | -2141 |
| Issuance (Retirement) of Debt, Net | -600477 | -415619 | -461609 | -253246 | -660504 |
| Foreign Exchange Effects | 28758 | 9549 | 3402 | 3324 | 12501 |
| Net Change in Cash | -116527 | -241882 | -358341 | -311301 | 328608 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Nomura Asset Management Co., Ltd. | Investment Advisor | 4.1084 | 65007007 | -76000 | 2023-02-28 | LOW |
| Sumitomo Mitsui Trust Asset Management Co., Ltd. | Investment Advisor | 3.8571 | 61030834 | 60943076 | 2022-11-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6692 | 42234586 | 57700 | 2023-02-28 | LOW |
| JPMorgan Securities Japan Co., Ltd. | Research Firm | 2.3848 | 37735000 | 13609000 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2293 | 35273592 | -840008 | 2023-02-28 | LOW |
| Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 2.0544 | 32507000 | 2470629 | 2022-11-30 | LOW |
| Daiwa Asset Management Co., Ltd. | Investment Advisor | 1.8823 | 29784238 | -48400 | 2023-02-28 | LOW |
| Nippon Life Insurance Company | Insurance Company | 1.861 | 29447000 | -2377000 | 2022-09-30 | LOW |
| Capital Research Global Investors | Investment Advisor | 1.8554 | 29358500 | 18800 | 2023-01-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.5239 | 24113047 | 1171849 | 2022-12-31 | LOW |
| Takeda Science Foundation | Corporation | 1.132 | 17912000 | 0 | 2022-09-30 | LOW |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd. | Investment Advisor | 0.778 | 12309837 | -65791 | 2023-02-28 | LOW |
| CPP Investment Board | Pension Fund | 0.7341 | 11616000 | 7985000 | 2022-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7089 | 11216737 | 13283 | 2023-02-28 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.5202 | 8230678 | 47200 | 2023-02-28 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.5143 | 8137797 | 8137597 | 2021-06-30 | LOW |
| M & G Investment Management Ltd. | Investment Advisor | 0.4559 | 7213600 | 0 | 2023-01-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4421 | 6994953 | 16400 | 2023-02-28 | LOW |
| California Public Employees' Retirement System | Pension Fund | 0.4418 | 6989926 | 722900 | 2022-06-30 | LOW |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.4359 | 6897836 | -59516 | 2023-02-28 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Takeda Pharmaceutical Company Limited Company profile
About Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Financial summary
BRIEF: For the nine months ended 31 December 2021, Takeda Pharmaceutical Co Ltd revenues increased 11% to Y2.696T. Net income applicable to common stockholders increased 35% to Y241.42B. Revenues reflect Intellectual Property And Service Revenue segment increase from Y69.04B to Y210.55B, Pharmaceutical Business segment increase of 5% to Y2.485T, Northern America segment increase of 9% to Y1.297T, Japan segment increase of 22% to Y530.25B.
Equity composition
FY'94-02 WAS were estimated. FY'04 Name changed from Takeda Chemical Industries, Ltd. to Takeda Pharmaceutical Company Limited. All 1&3Q, WAS were estimated and used as O/S. FY'08 Q3 WAS=O/S. FY'11 Q3 DWAS is estimated.
| Industry: | Pharmaceuticals (NEC) |
4階
日本橋本町二丁目1番1号
CHUO-KU
TOKYO-TO 103-8668
JP
Income Statement
- Annual
- Quarterly
News
XRP price prediction: How will the court case affect the price of ripple?
As its ongoing court case looks set to conclude, what might be next for XRP?
11:13, 28 March 2023
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
10:10, 28 March 2023
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com